A call to action on World Kidney Day, 8 March 2007
President, International Society of Nephrology
President, International Federation of Kidney Foundations
For the joint international Society of Nephrology/International Federation of Kidney Foundations World Kidney Day 2007 Steering Committee.
World Kidney Day—a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF) aims to spread the crucial message that ‘kidney disease is common, harmful and treatable’.
Common because chronic kidney disease (CKD), defined as a GFR of less than 60 ml/min and/or the presence of microalbuminuria or proteinuria, has now been consistently shown to affect about 10% of the adult population in studies of different races living on different continents world wide [1–5].
Harmful not just because some of these patients progress to end-stage renal disease (ESRD), but more because these renal abnormalities are associated with a many-fold increase in risk of cardiovascular complications and premature cardiovascular death [6,7]. Indeed, the risk of premature death, primarily from cardiovascular disease is, on average, 100-fold higher in patients with CKD than the risk of developing ESRD [8].
Treatable because there is now strong scientific evidence that early detection, altering lifestyle factors and aggressively controlling blood pressure, cannot only slow or halt the progression of patients with CKD to ESRD but can also significantly reduce the incidence of cardiovascular disease that leads to premature death in the majority of these patients [9–13].
Cardiovascular disease is today by far the most common cause of premature death worldwide [14]. We do not yet know exactly how many people dying of premature cardiovascular disease have CKD and might have benefited from early detection and treatment aimed at the kidney, but the number is certainly very large.
When we as a renal community become aware that early detection programs focused on the kidney can identify large numbers of patients who may be spared from other health complications or even premature death by simple interventions, we incur, in our view, a moral and ethical imperative to advocate for the implementation of such programs. That such programs can be successful and cost effective, has now been shown in several proof-of-concept prevention projects sponsored by the ISN and others [15–18].
The four major United States renal societies, in celebration of World Kidney Day 2007, have jointly described and called for a comprehensive change in both funding and delivery of renal health care in the US to emphasize early detection and prevention [19]. We strongly endorse their conclusions and recommendations and feel these could be adapted for cultural and economic realities in other developed and developing countries where there is also an urgent need for this message to be heard.
How can we deliver our message of prevention worldwide? One of the greatest challenges we face is ignorance about the kidneys. Surveys, even in better educated and developed countries, have shown that less than 5% of the population can provide accurate answers to questions about where the kidneys are located and what they do. This is because kidney disease, when viewed solely in the context of ESRD, is essentially an orphan disease affecting less than 0.2% of the population. And by that definition it does not even exist in many parts of the world where no renal replacement therapy options are available and therefore no patients with ESRD survive.
To overcome this ignorance about an ‘invisible’ disease like CKD, we will build on the remarkable success of the first World Kidney Day held on 9 March 2006 and celebrated in 45 countries around the world. The creativity shown by groups in all of these countries was extraordinary. Local events included walkathons, marathons, auctions, sales of T shirts and other paraphernalia, screening programs, educational seminars and media interviews. Meetings were arranged that led to proclamations and endorsement of World Kidney Day 2006 by a number of government officials in many cities, states and countries.
We want to capture and build on that remarkable local energy in 2007. ‘Tool kits’ have been made available to all renal organizations and contain suggestions for events, posters, and a variety of media releases that can be used in any language. We are encouraging the use of a simple slogan—‘Are your kidneys OK?’—to raise curiosity among the general public. Professional WKD staff in Brussels work with the WKD Steering Committee and Scientific Advisory Board to provide a coordinating centre for all WKD activities and maintain a website (www.worldkidneyday.org) that makes all informational materials available to anyone, free of charge.
But World Kidney Day 2007 is not only our cause at ISN or IFKF. It is a cause that involves all of us in the renal community worldwide—physicians, scientists, nurses and other health care providers, patients, administrators, health policy experts, government officials, nephrology organizations and foundations. All need to be aware of the ways in which more attention to the kidney in setting government policies can lead to major benefits to both patients and to health care budgets.
The readers of this editorial, mostly nephrologists, need to continue to be the outspoken advocates for our patients that we have always been. Especially now, when the discoveries we have made ourselves in the last decade put us in a much stronger position to demonstrate that increased awareness of the role of the kidney, particularly in the epidemic of diabetes and cardiovascular disease worldwide, can truly have a major impact on global public health.
We urge you to become involved in World Kidney Day this year and thereafter. Participate in events organized by your local societies and foundations, organize events if none is planned in your area, involve your hospitals and institutions, meet with local government officials such as mayors and public health officers, contact your local media and make yourself available for interviews and comments. And equally important—share with us and others what you are doing through the World Kidney Day website!
The message of World Kidney Day is that kidney disease is common harmful and treatable. On 8 March 2007, let us ensure that hundreds of thousands of people worldwide ask the question ‘Are your kidneys OK?’ and try to find out the answer.
 |
Notes |
|---|
Joel Kopple, MD, IFKF Executive Member; Paul Beerkens, IFKF President Elect; Anne Wilson, IFKF Secretary Treasurer; John Feehally, MD, ISN Secretary General; Thomas Reiser, ISN Executive Director; Miguel Riella, MD, ISN Committee Chair
|
References |
|---|
 Top References |
|---|
- Coresh J, Astor BC, Greene T, et al. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1–12.[ISI][Medline]
- Gansevoort RT, van der Heij B, Stegeman CA, et al. (2004) Trends in the incidence of treated end-stage renal failure in the Netherlands: hope for the future? Kidney Int Suppl 92, 7–10.
- Uhlig K, Macleod A, Craig J, et al. (2006) Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70:2058–2065.[ISI][Medline]
- El Nahas ME. (2005) The global challenge of chronic kidney disease (Nephrology Forum). Kidney Int 68:2918–2929.[CrossRef][ISI][Medline]
- Hallan SI, Coresh J, Astor BC, et al. (2006) International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk. J Am Soc Nephrol 17:2275–2284.
[Abstract/Free Full Text] - Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. New Engl J Med 351:1296–1305.
[Abstract/Free Full Text] - Weiner DE, Tabatabai S, Tighiouart H, et al. (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48:392–401.[CrossRef][ISI][Medline]
- Keith D, Nicholls G, Guillion C, et al. (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organisation. Arch Intern Med 164:659–663.
[Abstract/Free Full Text] - Mann JFE, Gerstein HC, Pogue J, et al. (2006) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134:629–636.
- Solomon SD, Rice MM, Jablonski KA, et al. (2006) Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114:26–33.
[Abstract/Free Full Text] - Asselbergs FW, Diercks GF, Hillege HL, et al. (2004) Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809–2816.
[Abstract/Free Full Text] - Ibsen H, Wachtell K, Olsen MH, et al. (2004) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Kidney Int 66:S56–S58.
- Yuyun MF, Adler AI, Wareham NJ. (2006) What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin in Nephrol Hypertension 14:271–276.
- World Health Organization. (2005) Preventing Chronic Diseases. A vital investment(World Health Organization, Geneva, Switzerland).
- Codreanu I, Perico N, Sharma SK, Schieppati A, Remuzzi G. (2006) Prevention programmes of progressive renal disease in developing nations. Nephrology 11:321–328.[CrossRef][Medline]
- Perico N, Plata R, Anabaya A, et al. (2005) Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. Kidney Int Suppl 97:S87–S94.[Medline]
- Mani MK. (2006) Nephrologists sans frontières: preventing chronic kidney disease on a shoestring. Kidney Int 70:821–823.[CrossRef][ISI][Medline]
- Atthobari J, Asselbergs FW, Boersma C, et al. (2006) Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the PREVEND and PREVEND-IT study. Clin Therapeutics 28:432–44.[CrossRef][ISI][Medline]
- Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. Chronic kidney disease: Common, harmful and treatable – World Kidney Day 2007. J Am Soc Nephrol (in press, February, 2007).
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||